Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

NCT05305131 PHASE2 RECRUITING

The investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabine in patients with locally advanced nasopharyngeal cancer (NPC)

Details

Lead sponsor	National University Hospital, Singapore
Phase	PHASE2
Status	RECRUITING
Enrolment	50
Start date	Mon Mar 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Nasopharyngeal Cancer

Interventions

• cisplatin and gemcitabine
• induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.

Countries

Singapore